Share This

Public company info - C-MER Eye Care Holdings Limited , 03309.HK

Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

C-MER Eye Care Holdings Limited, 03309.HK - Company Profile
Chairman LAM Shun Chiu Dennis
Share Issued (share) 1,147,000,000
Par Currency Hong Kong Dollar
Par Value 0.1
Industry Medical Equipment & Services
Corporate Profile Business Summary: The Group is principally engaged in the provision of ophthalmic services and sales of vision aid products in Hong Kong (“HK”) and Mainland China. Performance for the year: The Group’s total revenue during the year ended 31 December 2019 represented an increase of 34.2% as compared with the Group’s total revenue during the year ended 31 December 2018. The amount of gross profit during the year ended 31 December 2019 amounted to HK$191.3 million, representing an increase of 28.1% from HK$149.3 million during the year ended 31 December 2018. The Group’s gross profit margin was 33.2% during the year ended 31 December 2019, as compared with 34.8% during the year ended 31 December 2018. Business Review: Provision of ophthalmic services The ophthalmic services provided by us focused on surgeries for the treatment of not only cataract, glaucoma and strabismus, but also eye diseases including corneal and vitreoretinal diseases. Generally speaking, ophthalmic services provided by us are outpatient or day-care procedures, performed under local anaesthesia. Hence, unlike other hospitals, clinics or nursing homes, the Group are not constrained by bed capacity and do not focus on providing large inpatient facilities at the Group’s eye centres/hospitals or clinics. Sales of vision aid products The Group also generate revenue from the sales of vision aid products including glasses and lens. The sales were conducted by us through the assessment of the optometrists employed by us in Hong Kong and the Mainland China. During the year ended 31 December 2019, the Group’s revenue generated from the sales of vision aid products amounted to HK$47.7 million, representing an increase of 61.7% from that of last year. Prospects: The implementation of the favorable policies to the medical industry in the Mainland China, the development of the Guangdong-Hong Kong-Macau Greater Bay Area (粵港澳大灣區) and the increasing urbanisation and living standards of the middleclass population in the Mainland China are expected to stimulate the demand for high-quality ophthalmic services. The Group is prepared to exploit the business opportunity by implementing the following strategies: istablish or acquire eye hospitals, eye centre and clinics in Hong Kong and selected Mainland China cities including cities in Eastern China, Southwest or Central China and the Guangdong-Hong Kong-Macau Greater Bay Area; improve the Group’s operational capacity and service capability; and identify suitable strategic partners for collaboration.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.